SEATTLE–(BUSINESS WIRE)–#AlkylatingAgents–According to Coherent Market Insights, the global small molecule API
market was valued at US$ 126.6 million in 2017, and is projected to
exhibit a CAGR of 9.1% over the forecast period (2018–2026).
Key Trends and Analysis of the Small Molecule API Market:
Several active pharmaceutical ingredients manufacturers are expanding
their presence across the globe. The active pharmaceutical ingredients
(API) manufacturers are establishing their commercial production units
in Asia to remain competitive and gain advantage over other competitors.
Furthermore, in October 2017, active pharmaceutical ingredients
manufacturers Alcami, originally based in the U.S., opened an office in
Tokyo, Japan, as part of its effort to expand drug development and
manufacturing presence in Japan.
Market players are actively focused on mergers and acquisitions,
facility expansion to enhance the market share. For instance, in March
2019, GHO Capital, the European healthcare investor acquired a majority
stake in Sterling Pharma Solutions, a manufacturer of small molecule
APIs. Furthermore, in 2017, CordenPharma, a contract development
manufacturing organization (CDMO) invested US$ 4.1 million in the
manufacturing site infrastructure of its CordenPharma Switzerland
facility, thereby enhancing small molecule API development capacity.
North America holds a dominant position in the global small molecule API
market, owing to expansion strategies adopted by small molecule API
manufacturers. For instance, in 2017, Avista Pharma Solutions, a small
molecule API manufacturer, completed expansion of its Colorado-based
small molecule API manufacturing site, Longmont.
To know the latest trends and insights prevalent in this market,
click the link below:
Key Market Takeaways:
The global small molecule API market is expected to exhibit a CAGR of
9.1% during the forecast period (2018–2026), attributed to rising
prevalence of diseases such as cancer, cardiovascular, and infectious
diseases. For instance, according to the Centers for Disease Control
and Prevention (CDC), 2014, around 1.5 million cases of invasive
cancer, including around 15,000 cases among children younger than 20
years, and over 590,000 deaths from cancer were registered in the U.S.
Moreover, in January 2019, Cambrex Corporation, a manufacturer of
small molecule innovator and generic active pharmaceutical ingredients
(APIs) acquired Avista Pharma Solutions, a contract manufacturing
organization from Ampersand Capital Partners. The acquisition is
expected to provide Cambrex the access to its manufacturing facilities.
Key players operating in the global small molecule API market include
Lonza, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva
Pharmaceutical Industries Ltd., Pfizer, Inc., Aesica Pharmaceuticals
Ltd., Albemarle Corporation, Cambrex Corporation, BASF SE, Gland
Pharma Limited, Gilead Sciences, Inc., AstraZeneca Plc., Baxter
International Inc., Boehringer Ingelheim International GmbH, Celgene
Corporation, Piramal Pharma Solutions, Recipharm AB, Evonik Industries
AG, Glenmark Pharmaceuticals Limited, Siegfried AG, AbbVie Contract
Manufacturing, Aurinia Pharmaceuticals Inc., Bayer AG, Patheon, and
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2423
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave.
Email: [email protected]